
Anti-Inflammatory Agents Improve Outcomes and QOL in Cancer Patients
New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.
Two research results published in 2 different journals provide a common thread: anti-inflammatory agents can improve survival as well as quality of life (QOL) in cancer patients.
Scientists at the University of new Mexico observed a significant survival benefit in women with ovarian, fallopian tube or primary peritoneal cancer who had been administered perioperative ketorolac (an anti-inflammatory drug). Previous in vitro studies by the research group had identified inhibition of cytoskeletal remodeling by ketorolac via targeting of Rac1 and Cdc42, 2 Rho family GTPases.
In their current study, published in
Results from a trial, published in the
Omega-3 fatty acids, primarily sourced from marine organisms, have long been recognized as anti-inflammatory agents and have been shown to lower inflammation associated with chronic conditions such as heart disease and arthritis. The new studies add credibility to the use of these natural products as to improve cancer outcomes.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.